β1 and β2 Adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents

Allen Namath; Craig Chen; Rani Agrawal; Andrew J. Patterson

doi:10.1053/j.sane.2006.11.001

β1 and β2 Adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents

Allen Namath, Craig Chen, Rani Agrawal, Andrew J. Patterson

Anesthesiology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The human genome project may revolutionize our understanding of many cardiovascular diseases and the medications we use to treat them. Why are there variations in disease severity? What causes disease progression in some individuals but not others? Why are there such dramatic differences in response to some therapeutic agents? The human genome project may soon help us answer these questions for patients with disorders ranging from hypertension to congestive heart failure.

Original language	English (US)
Pages (from-to)	2-9
Number of pages	8
Journal	Seminars in Anesthesia, Perioperative Medicine and Pain
Volume	26
Issue number	1
DOIs	https://doi.org/10.1053/j.sane.2006.11.001
State	Published - Mar 2007

Keywords

Adrenergic receptor
Cardiomyopathy
Congestive heart failure
Haplotype
Hypertension
Myocardial infarction
Single nucleotide polymorphism
Sudden cardiac death
β Adrenergic receptor blocker

ASJC Scopus subject areas

Anesthesiology and Pain Medicine

Access to Document

10.1053/j.sane.2006.11.001

Fingerprint Dive into the research topics of 'β1 and β2 Adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents'. Together they form a unique fingerprint.

Cite this

β1 and β2 Adrenergic receptor polymorphisms : their impact on cardiovascular physiology, disease states, and response to therapeutic agents. / Namath, Allen; Chen, Craig; Agrawal, Rani; Patterson, Andrew J.

In: Seminars in Anesthesia, Perioperative Medicine and Pain, Vol. 26, No. 1, 03.2007, p. 2-9.

Research output: Contribution to journal › Article › peer-review

@article{d8491b3f8e8d4771b9a9d31c4322fcc5,

title = "β1 and β2 Adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents",

abstract = "The human genome project may revolutionize our understanding of many cardiovascular diseases and the medications we use to treat them. Why are there variations in disease severity? What causes disease progression in some individuals but not others? Why are there such dramatic differences in response to some therapeutic agents? The human genome project may soon help us answer these questions for patients with disorders ranging from hypertension to congestive heart failure.",

keywords = "Adrenergic receptor, Cardiomyopathy, Congestive heart failure, Haplotype, Hypertension, Myocardial infarction, Single nucleotide polymorphism, Sudden cardiac death, β Adrenergic receptor blocker",

author = "Allen Namath and Craig Chen and Rani Agrawal and Patterson, {Andrew J.}",

year = "2007",

month = mar,

doi = "10.1053/j.sane.2006.11.001",

language = "English (US)",

volume = "26",

pages = "2--9",

journal = "Journal of Critical Care",

issn = "0883-9441",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - β1 and β2 Adrenergic receptor polymorphisms

T2 - their impact on cardiovascular physiology, disease states, and response to therapeutic agents

AU - Namath, Allen

AU - Chen, Craig

AU - Agrawal, Rani

AU - Patterson, Andrew J.

PY - 2007/3

Y1 - 2007/3

N2 - The human genome project may revolutionize our understanding of many cardiovascular diseases and the medications we use to treat them. Why are there variations in disease severity? What causes disease progression in some individuals but not others? Why are there such dramatic differences in response to some therapeutic agents? The human genome project may soon help us answer these questions for patients with disorders ranging from hypertension to congestive heart failure.

AB - The human genome project may revolutionize our understanding of many cardiovascular diseases and the medications we use to treat them. Why are there variations in disease severity? What causes disease progression in some individuals but not others? Why are there such dramatic differences in response to some therapeutic agents? The human genome project may soon help us answer these questions for patients with disorders ranging from hypertension to congestive heart failure.

KW - Adrenergic receptor

KW - Cardiomyopathy

KW - Congestive heart failure

KW - Haplotype

KW - Hypertension

KW - Myocardial infarction

KW - Single nucleotide polymorphism

KW - Sudden cardiac death

KW - β Adrenergic receptor blocker

UR - http://www.scopus.com/inward/record.url?scp=33847249442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847249442&partnerID=8YFLogxK

U2 - 10.1053/j.sane.2006.11.001

DO - 10.1053/j.sane.2006.11.001

M3 - Article

AN - SCOPUS:33847249442

VL - 26

SP - 2

EP - 9

JO - Journal of Critical Care

JF - Journal of Critical Care

SN - 0883-9441

IS - 1

ER -